Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S R Denmeade

Showing results (31-40 of 33) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 33 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2012
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancerM J Morris, M A Eisenberger, R Pili, et al.
Biorxiv : the Preprint Server for Biology|February 8, 2024
LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancerA Mandl, S Jasmine, Teg Krueger, et al.
The Prostate|May 6, 2025
Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo-Controlled, Biomarker-Enriched Trial in Patients With the SOD2 Ala/Ala VariantA Mandl, M L Zahurak, N A Metri, et al.
Pageof 4

Showing results (31-40 of 33) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 33 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 4, 2012
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancerM J Morris, M A Eisenberger, R Pili, et al.
Biorxiv : the Preprint Server for Biology|February 8, 2024
LSD1 inhibition suppresses ASCL1 and de-represses YAP1 to drive potent activity against neuroendocrine prostate cancerA Mandl, S Jasmine, Teg Krueger, et al.
The Prostate|May 6, 2025
Muscadine Grape Skin Extract in Biochemically Recurrent Prostate Cancer: A Randomized, Placebo-Controlled, Biomarker-Enriched Trial in Patients With the SOD2 Ala/Ala VariantA Mandl, M L Zahurak, N A Metri, et al.
Pageof 4